Search QAs

We would like to clarify what exactly needs to be included for S.06.02 C0295 Crypto-assets. Are only directly held crypto assets to be included? EIOPA Q&A 2654 seems to indicate that only directly held crypto assets are to be included as per “if C0295 Crypto-assets has been completed with 1-4, then CIC code should be 'XX09'”. But does this new field consider non-direct exposure. For example how should the below be reported in this field: Equity of a large cryptocurrency exchange platform be included? Typically CIC3 e.g. ISIN US19260Q1076 A collective investment fund that tracks bitcoin. Typically CIC4 e.g. ISIN DE000A27Z304

1. Future Premiums for the Premium Provision Calculation under Solvency II: We have a question regarding the calculation of premium provisions. The present value of future premiums is a component of this calculation, and we would like to know if this component can be equal to zero other than the case of the premiums being paid fully before the inception of the coverage (considering that the policy is active).

For reporting e.g. in S.08.01, if there is no LEI code available, validation rule BV1243 does not allow the item "None" for "counterparty (group) code type". Yet the filing rules do allow that constellation. Could you please check this validation rule or clarify how to report in such cases?

How is the Member State in which the risk is situated determined in situations where policy covers multiple risks (where policy holder is NOT a legal person)? For example, where the insurance relates to a vehicle and in addition extra cover is included, like accident. Is it necessary to determine which is the Member State in which the risk is situated for each risk/insurance on the policy or does extra cover on the same policy follow the main risk? In the provided example, is the Member State of registration of the vehicle relevant for the accident insurance or are there two potential Member States in which the risk is situated-the Member State of registration of the vehicle and the Member State in which the habitual residence of the policy holder is situated?

Since the adoption of the Solvency II guidelines, have the financial market supervisory authorities both in Germany and Liechtenstein the authority to impose restructuring measures on insurance companies for life insurance policies, such as a temporary payment ban or a reduction in the insurance company's obligations, or whether the financial market supervision authority in Liechtenstein indeed does not have the authority to do so?

Are reinsurance transactions in Belgium collateralized? I.e. does a reinsurer needs to provide a collateral to a cedant, post placement?

Considering ECB add-on report E.04.01 examples and methods E.04.01: It would be very helpful to present clear example of splitting inv. revenues to EoAoL- and TP-movements. UL part seems more straightforward. And not artificial example but a real one, with decisions on how you split revenues between EoAoL and TP -movements, also for many different years, where there are cases where EoAoL movement in total is negative, and also TP movement is highly negative (due to interest rate movements etc.). E.04.01: Many companies does not have clear way to split inv. revenues (or expenses) to EoAoL or TP.

This question is for QRT S25.05. I am not able to select this in the template drop down list. For QRT S25.05 it is unclear were to report (and there for include) LAC DT and LAC TP. Can EIOPA give instruction in what Row(s) LAC DT and LAC TP should be reported?

Question 1
Article 9(2) of Commission Delegated Regulation (EU) 2015/35 provides that “insurance and reinsurance undertakings shall value assets and liabilities in accordance with international accounting standards adopted by the Commission pursuant to Regulation (EC) No 1606/2002 provided that those standards include valuation methods that are consistent with the valuation approach set out in Article 75 of Directive 2009/138/EC”.
As regards deferred taxes, the determination of net deferred tax assets depends on the valuation of deferred tax assets and deferred tax liabilities. Article 15(3) of Commission Delegated Regulation (EU) 2015/35 implies that insurers should elaborate a detailed scheduling of the timing of deferred tax assets, deferred tax liabilities